Journal article
Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial
RDA Lourenco, T Khoo, A Crothers, M Haas, R Montgomery, D Ball, M Bressel, S Siva
International Journal of Radiation Oncology Biology Physics | ELSEVIER SCIENCE INC | Published : 2022
Abstract
Purpose: The use of stereotactic ablative body radiation therapy (SABR) in advanced cancer care is increasing, yet the cost-effectiveness of single-fraction (SF) versus multifraction (MF) SABR in pulmonary oligometastases is unknown. Methods: A prespecified cost-effectiveness analysis was conducted of the Trans Tasman Radiation Oncology Group 13.01 - SAFRON II - randomized trial comparing SF with MF SABR in 87 patients with 133 pulmonary oligometastases. A partitioned survival model assessed costs and quality-adjusted life-years (QALY) over the within-trial period (4 years) and longer-term (10 years). Costs reflected a societal perspective, expressed in Australian dollars (A$) using 2020..
View full abstractGrants
Awarded by Bayer
Funding Acknowledgements
SAFRON II was funded by Cancer Australia through the Prioritydriven Collaborative Cancer Research Scheme APP1082399, and by the Auckland Medical Research Foundation grant APP2116004. SS was funded by the National Health and Medical Research Council (NHMRC) grant codes GNT1038399 and GNT1038399.